NCT06572319View on ClinicalTrials.gov

Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

August 1, 2026

Study Completion Date

December 31, 2026

Conditions
HER2-positive Gastric CancerHER2-positive Gastroesophageal Junction Adenocarcinoma
Interventions
DRUG

Disitamab Vedotin(RC48) Plus Tratuzumab

Disitamab Vedotin: 2.5mg/kg，ivgtt，D1, every 2 weeks for a treatment cycle. Tratuzumab: RP2D，ivgtt，D1, every 2 weeks for a treatment cycle.

Trial Locations (1)

310022

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors
lead

Zhejiang Cancer Hospital

OTHER